

Supplementary Material

Supplementary Table 1 List of 52 participating institutions

No.	Institution name
1	Chinese PLA General Hospital
2	The Fourth Affiliated Hospital of China Medical University
3	The General Hospital of Chinese People's Armed Police Forces
4	Tianjin Haibin People's Hospital
5	Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
6	Shanghai Pudong New Area Gongli Hospital
7	Shanghai East Hospital affiliated to Tongji University
8	The First Affiliated Hospital of Sun Yat-sen University
9	Beijing Ruijing Diabetes Hospital
10	Sun Yat-sen Memorial Hospital affiliated to Sun Yat-sen University
11	Guangdong Provincial Hospital of Traditional Chinese Medicine
12	Wuhan Asia Heart Hospital
13	The 305 Hospital of Chinese PLA
14	The Affiliated Hospital of Qingdao University
15	The Central Hospital of Shenyang Medical College
16	The 463 Hospital of Chinese PLA
17	Rocket Army Medical Center of Chinese PLA General Hospital
18	Peking Union Medical College Hospital affiliated to the Chinese Academy of Medical Sciences
19	Jiangsu Province Official Hospital
20	Longgang District Central Hospital of Shenzhen
21	The First Affiliated Hospital of Nanchang University
22	Zhongda Hospital of Southeast University
23	The Second People's Hospital of Foshan
24	The First Affiliated Hospital of Henan University of Science and Technology
25	The First People's Hospital of Shunde (Senior Department of Diagnosis and Treatment)
26	The First People's Hospital of Shunde (Department of Endocrinology)
27	The Second Affiliated Hospital of Nanchang University
28	General Hospital of Northern Theater Command of Chinese PLA (formerly the General Hospital of Shenyang Military Area Command of Chinese PLA)
29	Tianjin Hexi Ruijing Metabolic Disease Hospital
30	The Central Hospital of Wuhan


Supplementary Table 1 Continued

No.	Institution name
31	The General Hospital of Jinan Military Area Command of Chinese PLA
32	Guangzhou General Hospital of Guangzhou Military Area Command of Chinese PLA
33	Fuzhou General Hospital of Nanjing Military Command
34	Metabolic Disease Hospital of Tianjin Medical University
35	The Second Affiliated Hospital of Zhengzhou University
36	Nanjing Municipal Government Hospital
37	Chongqing Three Gorges Central Hospital
38	Tianjin NanKai Santan Hospital
39	Nanjing General Hospital of Nanjing Military Area Command of Chinese PLA
40	The First Hospital Affiliated to the Third Military Medical University (Southwest Hospital)
41	The 302 Hospital of Chinese PLA
42	Tangshan Gongren Hospital
43	Qingdao Municipal Hospital
44	Tianjin General Hospital of the Chinese People's Armed Police Forces
45	Shunde Hospital of Integrated Traditional Chinese and Western Medicine
46	Beijing Huaxin Hospital
47	Shenzhen Nanshan People's Hospital
48	Chengdu Ruien Diabetes Hospital
49	Tianjin Binhai New Area Dagang Hospital
50	Tianjin Hospital
51	Taian Central Hospital
52	Huadong Hospital Affiliated to Fudan University


Supplementary Table 2 Real-world usage of dual oral antidiabetic drugs in China

	Dual therapy	Number of patients	Proportion (%)
Vildagliptin dual therapy		933	
Vildagliptin + Biguanides		605	64.8
Vildagliptin + Metformin		604	64.7
Vildagliptin + α -Glucosidase inhibitor		121	13.0
Vildagliptin + Sulfonylurea		138	14.7
Vildagliptin + Thiazolidinediones		21	2.3
Vildagliptin + Glinides		48	5.2
Other dual oral antidiabetic therapy		670	
Metformin + Sulfonylurea		253	37.8
Metformin + α -Glucosidase inhibitor		159	23.7
Metformin + DPP-4 inhibitor		28	4.2
Metformin + Glinides		73	10.9
Metformin + Thiazolidinediones		23	3.4
α -Glucosidase inhibitor + Sulfonylurea		76	11.3
α -Glucosidase inhibitor + Glinides		22	3.3
α -Glucosidase inhibitor + Thiazolidinediones		10	1.5
Sulfonylurea + DPP-4 inhibitor		9	1.3
Sulfonylurea + Thiazolidinediones		8	1.2
Other combinations		9	1.3

DPP-4: dipeptidyl peptidase-4.



Supplementary Fig.1 Mean changes in HbA1c (%) in the vildagliptin add-on to metformin (VM) cohort and the dual oral antidiabetes agents, non-vildagliptin combination therapy (comparator) cohort after propensity score matching (n=530/cohort, full analysis set). * P<0.01, ** P<0.001. Error bars are standard deviations. Change from baseline between groups was compared with ANCOVA.



Supplementary Fig.2 Composite endpoint in the non-prespecified subgroups in the vildagliptin add-on to metformin (VM) cohort and dual oral antidiabetes agents, non-vildagliptin combination therapy (comparator) cohort after propensity score matching (full analysis set).